Valganciclovir (Valcyte®) powder for oral solution
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000359
Authors' recomendations: Valganciclovir (Valcyte®) powder for oral solution is recommended as an option for restricted use within NHS Wales for 200 days prophylaxis of cytomegalovirus (CMV) disease in CMV-negative kidney transplant patients who have received a transplant from a CMV-positive donor. Valganciclovir (Valcyte®) powder for oral solution is restricted for use in patients who cannot take tablets or with a CrCl<10 (ml/min). AWMSG is of the opinion that valganciclovir (Valcyte®) powder for oral solution is not suitable for shared care within NHS Wales for the above indication.
Project Status: Completed
Year Published: 2011
URL for published report: http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=177676&pid=24773
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Antiviral Agents
- Cytomegalovirus Infections
Organisation Name: All Wales Medicines Strategy Group
Contact Address: All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name: AWTTC@wales.nhs.uk
Contact Email: AWTTC@wales.nhs.uk
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.